NCT04885647已完成2 期
A Multicenter, Randomized, Open-label, Phase 2 Study of YPEG-rhEPO in Patients Suffered From Anemia Due to Chronic Kidney Disease, Who Has Previously Treated With rhEPO and Maintains the Hemoglobin in a Stabilize State
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 60
- 试验地点
- 17
- 主要终点
- Changes of mean hemoglobin compared to baseline.
研究概览
简要总结
The purpose of this study is to evaluate the effectiveness and safety of YPEG rhEPO, a recombinant human erythropoietin pegylated by Y shape polyethylene glycol, in patients with anemia due to Chronic Kidney Disease (CKD), assessed by hemoglobin maintenance, adverse events and health-related quality of life.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Aged between 18 and 70 years old, including 18 and 70 years.
- •Subjects who are diagnosed of chronic kidney disease and receiving hemodialysis (KT/V greater than or equal to 1.2). And those who had received hemodialysis, performed 2 to 3 times a week and 4 to 5 hours for every dialysis, for at least 12 weeks prior to deliver of YPEG-EPO.
- •Subjects receiving rhEPO treatment, including subcutaneous and intravenous injection, for anemia due to chronic kidney disease for at least 12 weeks before randomized. And in addition, the serum hemoglobin should keep stable during the previous 12 weeks, which was defined as serum hemoglobin obtained from tests taken once a month (once a month means at least 4 weeks interval between two tests) were always kept between 100g/L and 120g/L, or else mean hemoglobin of two different tests, which were taken at least 4 weeks apart, is between 100g/L and 120g/L.
- •Transferrin saturation (TSAT) greater than 20% or serum ferritin (SF) greater than 200ng/mL, serum folate greater or equal to the lower normal limit (ULN), serum vitamin B12 greater or equal to ULN，before enrollment.
- •Understand and sign the informed consent form voluntarily.
排除标准
- •Women of pregnancy, lactating, or planning to pregnant, or patients who are planning to donate sperms/eggs during the study period.
- •Subjects who are allergic to rhEPO or any of its components, or with any other evidenced allergy history that make it not suitable for participation.
- •Subjects who are receiving Roxadustat Capsules at screening.
- •Anemia caused by diseases or causes other than CKD, such as bleeding, hemolysis, vitamin or folate deficiency. Obvious bleeding evidence that requires blood transfusion during the lead-in period.
- •Subjects suffering from pure red-cell anemia (PRCA) according to previously erythropoietin treatment.
- •Subjects with serious disease or function deficiency in major organ/system, such as：
- •Medical history of myocardial infarction, cerebral stroke, vascular access thrombosis, or pulmonary embolism. Combined congestive heart failure (NYHA cardiac function equal to or grade than III). Hypertensions poorly controlled by medication (systolic blood pressure higher than 170mmHg and/or diastolic blood pressure higher than 100mmHg), or postural hypotension (systolic blood pressure below 90mmHg).
- •Medical history of malignancy, hematological disease, obvious bleeding disease, epilepsy, neuropsychiatric disease, or family history of neuropsychiatric disease.
- •Poorly controlled autoimmune diseases (including but not limit to systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, autoimmune thrombocytopenia).
- •Poorly controlled endocrine diseases, (including but not limit to thyroid disease, parathyroid disease, diabetes mellitus).
- •Co-infected with HAV, HBV, HCV, HIV, Syphilis, etc..
- •Currently suffering from severe infection or inflammation (C-reactive protein greater than 30mg / L), or currently receiving antibiotics.
- •Red blood cell count greater than 6.0×10^12/L for men while greater than 5.5×10^12/L for female; Platelets greater than 500×10^9/L; serum albumin lower than 30g/L; Alanine aminotransferase higher than 2 ULN, aspartame aminotransferase higher than 2ULN; Parathyroid hormone greater than 800pg/mL.
- •Subjects who plan to undergo coronary artery bypass grafting (CABG), to undergo orthopedic surgery, to receive kidney transplantation, or to undergo any other major operation during the study period.
- •Drug addicts or alcoholics.
- •Vascular malformations (such as internal jugular vein malformation) makes it inappropriately for Hemodialysis catheterization.
- •Expected survival of a certain subject is less than 12 months.
- •Subjects participated in any other clinical trial within 3 months prior to screening.
- •Any other situation that is not suitable for participation in this study according to the investigator's judgment.
研究组 & 干预措施
Arm1
Experimental
Low dose once every 2 weeks group
干预措施: YPEG-rhEPO (Drug)
Arm2
Experimental
Low dose once every 4 weeks group
干预措施: YPEG-rhEPO (Drug)
Arm3
Experimental
High dose once every 2 weeks group
干预措施: YPEG-rhEPO (Drug)
Arm4
Experimental
High dose once every 4 weeks group
干预措施: YPEG-rhEPO (Drug)
结局指标
主要结局
Changes of mean hemoglobin compared to baseline.
时间窗: 14 weeks for every two weeks groups, and 16 weeks for every four weeks groups.
次要结局
- Changes of hemoglobin compared to baseline at the time of first dose adjustment.(14 weeks for every two weeks groups, and 16 weeks for every four weeks groups.)
- Proportion of patients with hemoglobin fluctuations within ±10g/L compared to baseline.(14 weeks for every two weeks groups, and 16 weeks for every four weeks groups.)
- Mean time of hemoglobin keeping within the target range.(14 weeks for every two weeks groups, and 16 weeks for every four weeks groups.)
- Mean time from baseline to the first dose adjustment.(14 weeks for every two weeks groups, and 16 weeks for every four weeks groups.)
- Proportion of patients requiring blood transfusion.(14 weeks for every two weeks groups, and 16 weeks for every four weeks groups.)
- Proportion of patients with hemoglobin keeping within the target range (the target hemoglobin range is defined as hemoglobin keeping between 100g/L and 120g/L).(14 weeks for every two weeks groups, and 16 weeks for every four weeks groups.)
- Proportion of patients with dose adjustment.(14 weeks for every two weeks groups, and 16 weeks for every four weeks groups.)
研究者
研究点 (17)
Loading locations...
相似试验
终止
3 期
A Study of PEGylated Recombinant Human Hyaluronidase in Combination With Nab-Paclitaxel Plus Gemcitabine Compared With Placebo Plus Nab-Paclitaxel and Gemcitabine in Participants With Hyaluronan-High Stage IV Previously Untreated Pancreatic Ductal AdenocarcinomaPancreatic Ductal CarcinomaNCT02715804Halozyme Therapeutics492
已完成
3 期
Safety and Efficacy of PHP in the Treatment of Shock Associated With Systemic Inflammatory Response Syndrome (SIRS)ShockSystemic Inflammatory Response SyndromeNCT00021502Apex Bioscience1,000
已完成
不适用
The Clinical Study to Evaluate Immunogenicity of Epodion® in Anemia Associated With CKD PatientsChronic Kidney Disease (CKD)NCT05422755PT. Daewoong Infion200
已完成
3 期
Phase 3 Study to Evaluate the Safety and Efficacy of YPEG-rhG-CSF in Malignancies Receiving ChemotherapyNon-Myeloid MalignancyNCT04466137Xiamen Amoytop Biotech Co., Ltd.398
已完成
2 期
Study on the Efficacy and Safety of PEG-rhG-CSF in Preventing Neutropenia During Concurrent Chemoradiotherapy of Cervical CancerCervical CancerNCT04542356Chongqing University Cancer Hospital60